Mark P. McGovern
Research Subjects
Mark P. McGovern has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Haiyi Xie
10 shared publicationsChantal Lambert-Harris
Research Associate, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
5 shared publicationsAndrea Meier
4 shared publicationsElizabeth C. Saunders
3 shared publicationsRobert E. Drake
Dartmouth Psychiatric Research Center, Department of Psychiatry, and the Department of Community and Family Medicine , Dartmouth Medical School , Lebanon, NH, USA
3 shared publicationsArthur I. Alterman
University of Pennsylvania
2 shared publications
Latest Publications
- 1 March 2016
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 10 (2) , 117-123
Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders
Objectives: Rapidly escalating rates of heroin and prescription opioid use have been widely observed in rural areas across the United States. Although US Food and Drug Administration-approved medications for opioid use disorders exist, they are not routinely accessible to patients. One medication, buprenorphine, can be prescribed by waivered physicians in office-based practice settings, but practice patterns vary widely. This study explored the use of a learning collaborative method to improve the provision of buprenorphine in the state of Vermont. Methods: We initiated a learning collaborative with 4 cohorts of physician practices (28 total practices). The learning collaborative consisted of a series of 4 face-to-face and 5 teleconference sessions over 9 months. Practices collected and reported on 8 quality-improvement data measures, which included the number of patients prescribed buprenorphine, and the percent of unstable patients seen weekly. Changes from baseline to 8 months were examined using a p-chart and logistic regression methodology. Results: Physician engagement in the learning collaborative was favorable across all 4 cohorts (85.7%). On 6 of the 7 quality-improvement measures, there were improvements from baseline to 8 months. On 4 measures, these improvements were statistically significant (P < 0.001). Importantly, practice variation decreased over time on all measures. The number of patients receiving medication increased only slightly (3.4%). Conclusions: Results support the effectiveness of a learning collaborative approach to engage physicians, modestly improve patient access, and significantly reduce practice variation. The strategy is potentially generalizable to other systems and regions struggling with this important public health problem.
- 1 March 2016
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 10 (2) , 117-123
Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders
Objectives: Rapidly escalating rates of heroin and prescription opioid use have been widely observed in rural areas across the United States. Although US Food and Drug Administration-approved medications for opioid use disorders exist, they are not routinely accessible to patients. One medication, buprenorphine, can be prescribed by waivered physicians in office-based practice settings, but practice patterns vary widely. This study explored the use of a learning collaborative method to improve the provision of buprenorphine in the state of Vermont. Methods: We initiated a learning collaborative with 4 cohorts of physician practices (28 total practices). The learning collaborative consisted of a series of 4 face-to-face and 5 teleconference sessions over 9 months. Practices collected and reported on 8 quality-improvement data measures, which included the number of patients prescribed buprenorphine, and the percent of unstable patients seen weekly. Changes from baseline to 8 months were examined using a p-chart and logistic regression methodology. Results: Physician engagement in the learning collaborative was favorable across all 4 cohorts (85.7%). On 6 of the 7 quality-improvement measures, there were improvements from baseline to 8 months. On 4 measures, these improvements were statistically significant (P < 0.001). Importantly, practice variation decreased over time on all measures. The number of patients receiving medication increased only slightly (3.4%). Conclusions: Results support the effectiveness of a learning collaborative approach to engage physicians, modestly improve patient access, and significantly reduce practice variation. The strategy is potentially generalizable to other systems and regions struggling with this important public health problem.
- 18 August 2015
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 41 (6) , 527-534
Adherence and competence in two manual-guided therapies for co-occurring substance use and posttraumatic stress disorders: clinician factors and patient outcomes
For persons with substance use disorders, psychosocial therapies, such as motivational interviewing, cognitive behavioral therapy, twelve-step facilitation, and contingency management have demonstr...
- 18 August 2015
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 41 (6) , 527-534
Adherence and competence in two manual-guided therapies for co-occurring substance use and posttraumatic stress disorders: clinician factors and patient outcomes
For persons with substance use disorders, psychosocial therapies, such as motivational interviewing, cognitive behavioral therapy, twelve-step facilitation, and contingency management have demonstr...
A randomized controlled trial of treatments for co‐occurring substance use disorders and post‐traumatic stress disorder
Background and Aims: Post‐traumatic stress disorder (PTSD) is common among people with substance use disorders, and the comorbidity is associated with negative outcomes. We report on a randomized controlled trial comparing the effect of integrated cognitive–behavioral therapy (ICBT) plus standard care, individual addiction counseling plus standard care and standard care alone on substance use and PTSD symptoms.Design: Three‐group, multi‐site randomized controlled trial.Setting: Seven addiction treatment programs in Vermont and New Hampshire, USA.Participants/Cases: Recruitment took place between December 2010 and January 2013. In this single‐blind study, 221 participants were randomized to one of three conditions: ICBT plus standard care (SC) (n = 73), individual addiction counseling (IAC) plus SC (n = 75) or SC only (n = 73). One hundred and seventy‐two patients were assessed at 6‐month follow‐up (58 ICBT; 61 IAC; 53 SC). Intervention and comparators: ICBT is a manual‐guided therapy focused on PTSD and substance use symptom reduction with three main components: patient education, mindful relaxation and flexible thinking. IAC is a manual‐guided therapy focused exclusively on substance use and recovery with modules organized in a stage‐based approach: treatment initiation, early abstinence, maintaining abstinence and recovery. SC are intensive out‐patient program services that include 9–12 hours of face‐to‐face contact per week over 2–4 days of group and individual therapies plus medication management.Measurements: Primary outcomes were PTSD severity and substance use severity at 6 months. Secondary outcomes were therapy retention.Findings: PTSD symptoms reduced in all conditions with no difference between them. In analyses of covariance, ICBT produced more favorable outcomes on toxicology than IAC or SC [comparison with IAC, parameter estimate: 1.10; confidence interval (CI) = 0.17–2.04; comparison with SC, parameter estimate: 1.13; CI = 0.18–2.08] and had a greater reduction in reported drug use than SC (parameter estimate: –9.92; CI = –18.14 to –1.70). ICBT patients had better therapy continuation versus IAC (P<0.001). There were no unexpected or study‐related adverse events.Conclusions: Integrated cognitive behavioral therapy may improve drug‐related outcomes in post‐traumatic stress disorder sufferers with substance use disorder more than drug‐focused counseling, but probably not by reducing post‐traumatic stress disorder symptoms to a greater extent.
A randomized controlled trial of treatments for co‐occurring substance use disorders and post‐traumatic stress disorder
Background and Aims: Post‐traumatic stress disorder (PTSD) is common among people with substance use disorders, and the comorbidity is associated with negative outcomes. We report on a randomized controlled trial comparing the effect of integrated cognitive–behavioral therapy (ICBT) plus standard care, individual addiction counseling plus standard care and standard care alone on substance use and PTSD symptoms.Design: Three‐group, multi‐site randomized controlled trial.Setting: Seven addiction treatment programs in Vermont and New Hampshire, USA.Participants/Cases: Recruitment took place between December 2010 and January 2013. In this single‐blind study, 221 participants were randomized to one of three conditions: ICBT plus standard care (SC) (n = 73), individual addiction counseling (IAC) plus SC (n = 75) or SC only (n = 73). One hundred and seventy‐two patients were assessed at 6‐month follow‐up (58 ICBT; 61 IAC; 53 SC). Intervention and comparators: ICBT is a manual‐guided therapy focused on PTSD and substance use symptom reduction with three main components: patient education, mindful relaxation and flexible thinking. IAC is a manual‐guided therapy focused exclusively on substance use and recovery with modules organized in a stage‐based approach: treatment initiation, early abstinence, maintaining abstinence and recovery. SC are intensive out‐patient program services that include 9–12 hours of face‐to‐face contact per week over 2–4 days of group and individual therapies plus medication management.Measurements: Primary outcomes were PTSD severity and substance use severity at 6 months. Secondary outcomes were therapy retention.Findings: PTSD symptoms reduced in all conditions with no difference between them. In analyses of covariance, ICBT produced more favorable outcomes on toxicology than IAC or SC [comparison with IAC, parameter estimate: 1.10; confidence interval (CI) = 0.17–2.04; comparison with SC, parameter estimate: 1.13; CI = 0.18–2.08] and had a greater reduction in reported drug use than SC (parameter estimate: –9.92; CI = –18.14 to –1.70). ICBT patients had better therapy continuation versus IAC (P<0.001). There were no unexpected or study‐related adverse events.Conclusions: Integrated cognitive behavioral therapy may improve drug‐related outcomes in post‐traumatic stress disorder sufferers with substance use disorder more than drug‐focused counseling, but probably not by reducing post‐traumatic stress disorder symptoms to a greater extent.
- 1 January 2015
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 47 (1) , 42-50
The Prevalence of Posttraumatic Stress Disorder Symptoms among Addiction Treatment Patients with Cocaine Use Disorders
Co-occurring cocaine use and posttraumatic stress disorders are prevalent and associated with negative treatment, health and societal consequences. This study examined the relationships among PTSD symptoms, gender, and cocaine use problems. Within a cross-sectional design, we gathered archival point prevalence data on new admissions (n = 573) to three addiction treatment agencies. Demographic, substance use, and PTSD symptom information were collected across the three agencies. Logistic regression analyses revealed that patients with cocaine use disorders had a two-fold increased odds for a probable PTSD diagnosis, compared to patients without a cocaine use disorder (OR = 2.19, 95% CI = 1.49–3.22, p < 0.001). Among females with cocaine use disorder, multinomial regression yielded a significant increase in the risk of moderate (RRR = 2.12, 95% CI = 1.10–4.10, p < 0.05) and severe (RRR = 2.87, 95% CI = 1.33–6.21, p < 0.01) PTSD symptoms. Males with cocaine use disorders had a two-fold increase in the risk of moderate PTSD symptoms (RRR = 2.13, 95% CI = 1.23–3.68, p < 0.01), but had no increased risk of developing severe PTSD symptoms (RRR = 1.93, 95% CI = 0.85–4.39, p = 0.117). Cocaine use appears to impact the risk of PTSD symptoms, especially in females. Future research should explore the generalizability of these findings to more racially and ethnically diverse samples, as well as among persons with this comorbidity who are not engaged in treatment services.
- 1 January 2015
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 47 (1) , 42-50
The Prevalence of Posttraumatic Stress Disorder Symptoms among Addiction Treatment Patients with Cocaine Use Disorders
Co-occurring cocaine use and posttraumatic stress disorders are prevalent and associated with negative treatment, health and societal consequences. This study examined the relationships among PTSD symptoms, gender, and cocaine use problems. Within a cross-sectional design, we gathered archival point prevalence data on new admissions (n = 573) to three addiction treatment agencies. Demographic, substance use, and PTSD symptom information were collected across the three agencies. Logistic regression analyses revealed that patients with cocaine use disorders had a two-fold increased odds for a probable PTSD diagnosis, compared to patients without a cocaine use disorder (OR = 2.19, 95% CI = 1.49–3.22, p < 0.001). Among females with cocaine use disorder, multinomial regression yielded a significant increase in the risk of moderate (RRR = 2.12, 95% CI = 1.10–4.10, p < 0.05) and severe (RRR = 2.87, 95% CI = 1.33–6.21, p < 0.01) PTSD symptoms. Males with cocaine use disorders had a two-fold increase in the risk of moderate PTSD symptoms (RRR = 2.13, 95% CI = 1.23–3.68, p < 0.01), but had no increased risk of developing severe PTSD symptoms (RRR = 1.93, 95% CI = 0.85–4.39, p = 0.117). Cocaine use appears to impact the risk of PTSD symptoms, especially in females. Future research should explore the generalizability of these findings to more racially and ethnically diverse samples, as well as among persons with this comorbidity who are not engaged in treatment services.
- 19 January 2013
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 40 (2) , 234-241
Assessing the Co-occurring Capability of Mental Health Treatment Programs: the Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index
The Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index was developed to assess the capability of mental health programs to provide substance abuse and co-occurring treatment services. The DDCMHT is an objective scale rated following a site visit that includes semi-structured interviews with staff at all levels, review of program documents and client charts, and ethnographic observation of the milieu and setting. Using data from 67 mental health programs across six states, this study found that the DDCMHT had excellent total score reliability, variable subscale reliability, high inter-rater reliability (n = 18), and moderate construct validity (n = 22). Results also suggest that many mental health programs are at a relatively low level of capability for the delivery of care to individuals with co-occurring disorders. Results from this important new benchmark measure, the DDCMHT, can be used with programs in implementation planning and with treatment systems, states, or national organizations to guide policy change.
- 19 January 2013
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 40 (2) , 234-241
Assessing the Co-occurring Capability of Mental Health Treatment Programs: the Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index
The Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) Index was developed to assess the capability of mental health programs to provide substance abuse and co-occurring treatment services. The DDCMHT is an objective scale rated following a site visit that includes semi-structured interviews with staff at all levels, review of program documents and client charts, and ethnographic observation of the milieu and setting. Using data from 67 mental health programs across six states, this study found that the DDCMHT had excellent total score reliability, variable subscale reliability, high inter-rater reliability (n = 18), and moderate construct validity (n = 22). Results also suggest that many mental health programs are at a relatively low level of capability for the delivery of care to individuals with co-occurring disorders. Results from this important new benchmark measure, the DDCMHT, can be used with programs in implementation planning and with treatment systems, states, or national organizations to guide policy change.
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 7 (1) , 25-32
Organizational Capacity to Address Co-occurring Substance Use and Psychiatric Disorders
Objectives: There is widespread recognition that services to persons with co-occurring substance use and psychiatric disorders should be accessible, yet most persons with these disorders do not receive care for both problems. Estimates of available services vary widely and have not examined potential variation by level of care. Methods: The present study samples 180 community addiction treatment programs and utilizes a standardized observational assessment of these programs using the dual diagnosis capability of addiction treatment (DDCAT) index. By level of care, the sample consisted of 53 outpatient programs, 50 intensive outpatient programs, and 77 residential programs. Results: Overall, approximately 81.1% of programs across levels of care offered addiction-only services, 18.3% dual diagnosis capable services, and less than 1% dual diagnosis enhanced services. Relative to residential and intensive outpatient programs, outpatient programs were more likely to have greater dual diagnosis capability (dual diagnosis capable services). Outpatient programs scored significantly higher on the DDCAT dimensions associated with program policies and continuity of care. Specific DDCAT benchmark items revealing detailed differences were found in these dimensions and specific assessment and treatment practices. Access to physician-prescriber or to psychotropic medications did not differ by level of care. Conclusions: The findings suggest that across levels of care, addiction-treatment systems and programs must continue to improve capacity for patients with co-occurring disorders. The application of a standardized, objective, and observational instrument may be useful to guide and measure the effectiveness of these efforts.
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 7 (1) , 25-32
Organizational Capacity to Address Co-occurring Substance Use and Psychiatric Disorders
Objectives: There is widespread recognition that services to persons with co-occurring substance use and psychiatric disorders should be accessible, yet most persons with these disorders do not receive care for both problems. Estimates of available services vary widely and have not examined potential variation by level of care. Methods: The present study samples 180 community addiction treatment programs and utilizes a standardized observational assessment of these programs using the dual diagnosis capability of addiction treatment (DDCAT) index. By level of care, the sample consisted of 53 outpatient programs, 50 intensive outpatient programs, and 77 residential programs. Results: Overall, approximately 81.1% of programs across levels of care offered addiction-only services, 18.3% dual diagnosis capable services, and less than 1% dual diagnosis enhanced services. Relative to residential and intensive outpatient programs, outpatient programs were more likely to have greater dual diagnosis capability (dual diagnosis capable services). Outpatient programs scored significantly higher on the DDCAT dimensions associated with program policies and continuity of care. Specific DDCAT benchmark items revealing detailed differences were found in these dimensions and specific assessment and treatment practices. Access to physician-prescriber or to psychotropic medications did not differ by level of care. Conclusions: The findings suggest that across levels of care, addiction-treatment systems and programs must continue to improve capacity for patients with co-occurring disorders. The application of a standardized, objective, and observational instrument may be useful to guide and measure the effectiveness of these efforts.
- 1 January 2013
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 44 (1) , 1-3
Substance abuse treatment implementation research
- 1 January 2013
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 44 (1) , 1-3
Substance abuse treatment implementation research
- 1 December 2012
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 43 (4) , 402-409
Development and initial feasibility of an organizational measure of behavioral health integration in medical care settings
- 1 December 2012
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 43 (4) , 402-409
Development and initial feasibility of an organizational measure of behavioral health integration in medical care settings
- 27 November 2012
- Published by Springer Nature in Administration and Policy in Mental Health and Mental Health Services Research
- Vol. 41 (2) , 205-214
Dual Diagnosis Capability in Mental Health and Addiction Treatment Services: An Assessment of Programs Across Multiple State Systems
Despite increased awareness of the benefits of integrated services for persons with co-occurring substance use and psychiatric disorders, estimates of the availability of integrated services vary widely. The present study utilized standardized measures of program capacity to address co-occurring disorders, the dual diagnosis capability in addiction treatment and dual diagnosis capability in mental health treatment indexes, and sampled 256 programs across the United States. Approximately 18 % of addiction treatment and 9 % of mental health programs met criteria for dual diagnosis capable services. This is the first report on public access to integrated services using objective measures.
- 27 November 2012
- Published by Springer Nature in Administration and Policy in Mental Health and Mental Health Services Research
- Vol. 41 (2) , 205-214
Dual Diagnosis Capability in Mental Health and Addiction Treatment Services: An Assessment of Programs Across Multiple State Systems
Despite increased awareness of the benefits of integrated services for persons with co-occurring substance use and psychiatric disorders, estimates of the availability of integrated services vary widely. The present study utilized standardized measures of program capacity to address co-occurring disorders, the dual diagnosis capability in addiction treatment and dual diagnosis capability in mental health treatment indexes, and sampled 256 programs across the United States. Approximately 18 % of addiction treatment and 9 % of mental health programs met criteria for dual diagnosis capable services. This is the first report on public access to integrated services using objective measures.